BioInvent, Pfizer sign antibody deal
BioInvent International AB licensed Pfizer Inc. rights to develop and commercialize antibodies targeting an undisclosed number tumor-associated myeloid cells.
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.